PharVision Advisers’s DexCom DXCM Stock Holding History

PharVision Advisers’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,131	Closed	-$208K	–	266
2025 Q4	$208K	Buy	+3,131	New	+$202K	0.11%	525

Other funds holding DXCM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PharVision Advisers's DXCM Position: Q1 2026 in Review

PharVision Advisers sold out of DexCom (DXCM) in Q1 2026, closing a stake of 3,131 shares — an estimated $208K sold.

PharVision Advisers first reported a position in DXCM in Q4 2025 and held it in 1 quarter. The position peaked at $208K in Q4 2025. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

PharVision Advisers reported no remaining DexCom position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 3,131 DexCom shares in Q1 2026, an estimated $208K.
PharVision Advisers first reported a position in DexCom in Q4 2025 and held it in 1 quarter.
PharVision Advisers's DexCom position peaked at $208K in Q4 2025.
956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.